Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2019 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$1.69 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 9.03% year-over-year to -$1.69; the TTM value through Mar 2026 reached -$7.25, down 164.5%, while the annual FY2025 figure was -$7.12, 161.17% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$1.69 in Q1 2026 for Agios Pharmaceuticals, up from -$1.85 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $16.22 in Q3 2024 and bottomed at -$1.93 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.47, with a median of -$1.68 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 356.72% in 2023 and then skyrocketed 1089.02% in 2024.
  • Agios Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.67 in 2022, then crashed by 356.72% to -$1.72 in 2023, then fell by 1.16% to -$1.74 in 2024, then fell by 6.32% to -$1.85 in 2025, then grew by 8.65% to -$1.69 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$1.69, -$1.85, and -$1.78 for Q1 2026, Q4 2025, and Q3 2025 respectively.